Research
Optimal levetiracetam dosage regimen for preventing seizures related to immune effector cell-associated neurotoxicity syndrome
Nature ·
The Brief
- A study published on nature.com examines the optimal levetiracetam dosage regimen for preventing seizures linked to immune effector cell-associated neurotoxicity syndrome (ICANS) after CAR-T therapy.
- The source provided contains only the title and no summary, so specific findings and dosing results are not available here.
Why it matters
Seizures are a neurotoxic complication of CAR-T therapy, so evidence on the dosing regimen used to prevent them matters for clinicians managing these patients.
Who’s affected
- clinicians treating patients receiving CAR-T therapy
- patients receiving CAR-T therapy
- #car-t
- #levetiracetam
- #neurotoxicity
- #seizures
- #clinical-dosing